Seres Therapeutics (MCRB) Other Operating Expenses (2014 - 2026)
Seres Therapeutics (MCRB) posted Other Operating Expenses of $592000.0 for Q4 2025, down 19.57% sequentially from $736000.0 in Q3 2025, and down 83.24% YoY from $3.5 million in Q4 2024.
Seres Therapeutics (MCRB) Other Operating Expenses (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Other Operating Expenses for 8 years, with the latest figure at $592000.0 in Q4 2025.
- Quarterly Other Operating Expenses fell 83.24% year-over-year to $592000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 73.52% YoY) and the FY2025 annual result came in at $6.5 million, up 85.28% from the prior year.
- Other Operating Expenses retreated to $592000.0 in Q4 2025 per MCRB's latest filing, from $736000.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $32.0 million in Q1 2023 and troughed at -$346000.0 in Q4 2022.
- A 5-year average of $3.4 million and a median of $976000.0 in 2022 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Operating Expenses plunged 157.19% in 2022, then soared 3174.9% in 2023.
- Over 5 years, Other Operating Expenses stood at $605000.0 in 2021, then slumped by 157.19% to -$346000.0 in 2022, then jumped by 708.67% to $2.1 million in 2023, then surged by 67.71% to $3.5 million in 2024, then plunged by 83.24% to $592000.0 in 2025.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $592000.0, $736000.0, and $185000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.00 Mn |
| Dec 31, 2025 | 592,000.00 |
| Sep 30, 2025 | 736,000.00 |
| Jun 30, 2025 | 185,000.00 |
| Mar 31, 2025 | 2.18 Mn |
| Dec 31, 2024 | 3.53 Mn |
| Jun 30, 2023 | 2.11 Mn |
| Mar 31, 2023 | 31.96 Mn |
| Dec 31, 2022 | -346,000.00 |
| Sep 30, 2022 | 1.05 Mn |
| Jun 30, 2022 | -271,000.00 |
| Mar 31, 2022 | 976,000.00 |
| Dec 31, 2021 | 605,000.00 |
| Sep 30, 2021 | 1.13 Mn |
| Dec 31, 2016 | 16,000.00 |
| Jun 30, 2015 | -220,000.00 |
| Mar 31, 2015 | -220,000.00 |
| Dec 31, 2014 | -914,000.00 |
| Sep 30, 2014 | -521,000.00 |
| Jun 30, 2014 | -3,000.00 |